Download Image
    
Share
  
Post
Ebselen for COVID-19
2 studies with 56 patients
Hospital Icon Control
Hospital Icon Ebselen Serious Outcome Risk
No significant improvements are seen in meta-analysis to date.
COVID-19 Ebselen studies. Jul 2026. c19early.org
0 0.5 1 1.5+ All studies -130% Mortality -130% Recovery -17% RCTs -130% RCT mortality -130% Late -130% Favorsebselen Favorscontrol
Jul 1
 Covid Analysis Meta-analysis of ebselen studies
Meta-analysis of ebselen studies
Jun 29
 Treggiari et al., NCT04483973 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients
125% higher mortality (p=0.62) and 13% worse recovery (p=0.78). RCT 25 severe COVID-19 patients showing no significant differences with SPI-1005 (ebselen).
Jun 25
 Treggiari et al., NCT04484025 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients
141% higher mortality (p=1) and 21% worse recovery (p=0.67). RCT 31 moderate COVID-19 patients showing no significant differences with SPI-1005 (ebselen).